Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peflutren Lipid Microsphere Injectable · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Peflutren Lipid Microsphere Injectable Suspension | DRUG | - |
Inclusion Criteria: * Diagnosed with 1 but \<7 focal liver lesions * Scheduled for liver biopsy within 30 days of study * Scheduled for CT or MR within 30 days of study Exclusion Criteria: * Critically ill subjects * Subjects with right-to-left shunts
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986435 |
| Exelixis, Inc. | EXEL | 1 | PHASE1 | Zanzalintinib |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | Nemtabrutinib |
| Vir Biotechnology, Inc. | VIR | 1 | PHASE1 | VIR-2218, VIR-3434 |
| Pfizer Inc. | PFE | 1 | PHASE1 | PF-07328948 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | SWTX | 1 | PHASE1 | Mirdametinib |
Peflutren Lipid Microsphere Injectable is an investigational drug being studied for use in liver disease, specifically to assess focal liver lesions. It is currently in Phase 2 clinical development and is not approved by the FDA.
Peflutren Lipid Microsphere Injectable is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH.
Peflutren Lipid Microsphere Injectable is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA.
Peflutren Lipid Microsphere Injectable has one completed Phase 2 clinical trial, identified as NCT00162058, titled "A Phase II Study of DMP 115 to Assess Focal Liver Lesions." The trial enrolled 80 participants in the United Kingdom.
Yes, Peflutren Lipid Microsphere Injectable is also known as DMP 115. The Phase 2 clinical trial NCT00162058 refers to the drug as DMP 115 in its title.